Genprex

NASDAQ : GNPX

MANAGEMENT TEAM:

Rodney Varner JD, Founder & Chief Executive Officer
Julien Pham MD, MPH, President & Chief Operating Officer
Ryan Confer MS, Chief Financial Officer
James Rothman, PhD, Strategic Advisor to the Board

BOARD OF DIRECTORS:

Rodney Varner JD, Chairman
Bob Pearson, Experience Global Pharma Communications
David Friedman JD, Experience Finance & Compliance

SCIENTIFIC ADVISORY BOARD:

Jack Roth, MD, Scientific Founder & Chairman
George Simon, MD
Pasi Antero Janne, MD, PhD
Tony S.K. Mok, MD

INTELLECTUAL PROPERTY:

30+ Patents Issued, 2 Pending
MD Anderson Cancer Center, NIH NCI

AN UNMET MEDICAL NEED: LUNG CANCER

- Second-most common cancer
- Non-small cell lung cancer (NSCLC) represents 80% of all lung cancers
- 225,000 new cases per year in the U.S; 1.8 million cases worldwide
- Five-year survival rate for Stage IV NSCLC approx. 1%

ONCOPREX™ COMPETITIVE ADVANTAGE:

- Clinically proven to selectively kill cancer cells while sparing normal cells
- 10- to 25-fold uptake by tumor cells over normal cells
- Harness the body's natural tumor-suppressing mechanisms to detect and destroy cancer cells
- Provide therapeutic benefit to patients who have developed resistance to EGFR inhibitors
- Combination with approved products could unlock NSCLC market for patients that cannot benefit from existing therapies
- Significant cancer-killing synergy when combined with a variety of kinase inhibitors including those targeting EGFR and AKT, and with checkpoint inhibitors

KEY RESEARCH COLLABORATIONS:

UT MD Anderson Cancer Center
UT Health Science Center San Antonio

CONTACT INFORMATION:

1601 Trinity Street, Bldg. B, Suite #3.322
Austin, Texas 78712
Tel: (512) 537-7997
Email: info@genprex.com
Web: www.genprex.com

COMPANY & PLATFORM OVERVIEW

Genprex (NASDAQ : GNPX) is a clinical-stage biopharmaceutical company developing novel gene therapies to improve outcomes for cancer patients receiving promising targeted and immunotherapies, as well as to expand therapeutic benefits to a greater number of patients. The Company's unique approach to cancer treatment is grounded in its proprietary gene therapy platform with broad application to utilize multiple tumor suppressor genes, provide synergies with multiple approved therapies, and address a range of cancer indications. Genprex's lead product candidate, Oncoprex™, has been developed on this cutting-edge platform and combines the features of gene therapy and immunotherapy to provide a multimodal approach to treating cancer.

AN UNMET MEDICAL NEED: LUNG CANCER

Lung cancer is the second-most common cancer and the leading cause of cancer deaths worldwide with 1.6 million deaths annually. NSCLC represents about 80% of all lung cancer diagnoses. Survival for NSCLC has not improved markedly in 25 years and the five-year survival rate for stage IV NSCLC is approximately 1%. Chemotherapies have significant side effects that increase patient suffering and degrade quality of life. Currently approved targeted therapies for advanced NSCLC are only effective in a minority of patients and eventually most patients become resistant to the treatments.

R&D PIPELINE AND PATH TO APPROVAL



LEAD CANDIDATE ONCOPREX

Oncoprex (DOTAP:Chol-TUSC2) is a unique, first-in-class, immunogene therapy in development as a treatment for non-small cell lung cancer (NSCLC).

By combining the features of gene therapy and immunotherapy, Oncoprex has been shown to increase the expression of the tumor suppressor TUSC2 inside the cancer cell, leading to intracellular regulation of signal transduction and programmed cell death. It has also been shown to prime the tumor cell microenvironment, including through down-regulation of PD-L1 receptors and upregulation of NK and CD8+ T-cells, thereby boosting the innate immune system's response to cancer. Oncoprex, in combination with an EGFR inhibitor, has shown synergistic anti-cancer activity in pre-clinical and clinical studies. Pre-clinical data also demonstrates that Oncoprex in combination with an anti-PD1 inhibitor provides greater anti-tumor effect compared to monotherapy and may be a complementary therapeutic option for patients with difficult-to-treat lung cancer.

The University of Texas MD Anderson Cancer Center in Houston is conducting a Phase I/II clinical trial for Oncoprex treatment of NSCLC in combination with FDA-approved erlotinib. A Phase I trial of Oncoprex as a monotherapy was completed in 2012 and established baseline safety in human patients. Genprex plans to expand the current combination erlotinib-Oncoprex trial to multiple centers. We also plan to launch a Phase I/II trial of combination anti-PD1 inhibitor with Oncoprex.

TARGET MARKET OPPORTUNITY

Our Phase I/II trial is evaluating Oncoprex in combination with the tyrosine kinase inhibitor (TKI), erlotinib. While erlotinib is a blockbuster drug (over $1B in sales in 2015), it cannot help many lung cancer patients who do not have the activating EGFR mutation (~90% of NSCLC population). Additionally, most patients who do benefit from erlotinib eventually become resistent to therapy and experience further disease progression. Oncoprex has the potential to unlock the TKI market and expand treatment indication for lung cancer patients who have previously been ineligible or become resistant to treatment. Pre-clinical data also demonstrates that Oncoprex is synergistic with anti PD1s, thus potentially allowing access to the large and growing immunotherapy market for lung cancer.